Emodin Improves Renal Fibrosis in Chronic Kidney Disease by Regulating Mitochondrial Homeostasis Through the Mediation of Peroxisome Proliferator-activated Receptor-gamma Coactivator-1 Alpha (PGC-1α)

Overview

Journal Eur J Histochem

Specialty Biochemistry

Date 2024 May 14

PMID 38742403

Authors

Liuchang Feng

Zaoqiang Lin

Zeyong Tang

Lin Zhu

Shu Xu

Xi Tan

Xinyuan Wang

Jianling Mai

Qinxiang Tan

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is a leading public health issue associated with high morbidity worldwide. However, there are only a few effective therapeutic strategies for CKD. Emodin, an anthraquinone compound from rhubarb, can inhibit fibrosis in tissues and cells. Our study aims to investigate the antifibrotic effect of emodin and the underlying molecular mechanism. A unilateral ureteral obstruction (UUO)-induced rat model was established to evaluate the effect of emodin on renal fibrosis development. Hematoxylin and eosin staining, Masson's trichrome staining, and immunohistochemistry staining were performed to analyze histopathological changes and fibrotic features after emodin treatment. Subsequently, a transforming growth factor-beta 1 (TGF-β1)-induced cell model was used to assess the inhibition of emodin on cell fibrosis in vitro. Furthermore, Western blot analysis and real-time quantitative reverse transcription-polymerase chain reaction were performed to validate the regulatory mechanism of emodin on renal fibrosis progression. As a result, emodin significantly improved histopathological abnormalities in rats with UUO. The expression of fibrosis biomarkers and mitochondrial biogenesis-related proteins also decreased after emodin treatment. Moreover, emodin blocked TGF-β1-induced fibrotic phenotype, lipid accumulation, and mitochondrial homeostasis in NRK-52E cells. Conversely, peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α) silencing significantly reversed these features in emodin-treated cells. Collectively, emodin plays an important role in regulating PGC-1α-mediated mitochondria function and energy homeostasis. This indicates that emodin exhibits great inhibition against renal fibrosis and acts as a promising inhibitor of CKD.

Citing Articles

Renal Health Through Medicine-Food Homology: A Comprehensive Review of Botanical Micronutrients and Their Mechanisms.

Zhao Y, Song J, Feng R, Hu J, Xu H, Ye M Nutrients. 2024; 16(20).

PMID: 39458524 PMC: 11510533. DOI: 10.3390/nu16203530.

References

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

Meng X, Nikolic-Paterson D, Lan H . TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6):325-38. DOI: 10.1038/nrneph.2016.48. View

Ma L, Li H, Zhang S, Xiong X, Chen K, Jiang P . Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2. Int Urol Nephrol. 2017; 50(2):373-382. DOI: 10.1007/s11255-017-1757-x. View

Nogueira A, Pires M, Oliveira P . Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. In Vivo. 2017; 31(1):1-22. PMC: 5354133. DOI: 10.21873/invivo.11019. View

Tontonoz P, Hu E, Spiegelman B . Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994; 79(7):1147-56. DOI: 10.1016/0092-8674(94)90006-x. View

Liu Y . Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006; 69(2):213-7. DOI: 10.1038/sj.ki.5000054. View

Munoz-Felix J, Martinez-Salgado C . Dissecting the Involvement of Ras GTPases in Kidney Fibrosis. Genes (Basel). 2021; 12(6). PMC: 8225075. DOI: 10.3390/genes12060800. View

Yang F, Deng L, Li J, Chen M, Liu Y, Hu Y . Emodin Retarded Renal Fibrosis Through Regulating HGF and TGFβ-Smad Signaling Pathway. Drug Des Devel Ther. 2020; 14:3567-3575. PMC: 7478377. DOI: 10.2147/DDDT.S245847. View

Eddy A . Molecular basis of renal fibrosis. Pediatr Nephrol. 2001; 15(3-4):290-301. DOI: 10.1007/s004670000461. View

10.

Zschiedrich S, Bork T, Liang W, Wanner N, Eulenbruch K, Munder S . Targeting mTOR Signaling Can Prevent the Progression of FSGS. J Am Soc Nephrol. 2017; 28(7):2144-2157. PMC: 5491276. DOI: 10.1681/ASN.2016050519. View

11.

Lin J, Handschin C, Spiegelman B . Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005; 1(6):361-70. DOI: 10.1016/j.cmet.2005.05.004. View

12.

Martinez-Klimova E, Aparicio-Trejo O, Tapia E, Pedraza-Chaverri J . Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments. Biomolecules. 2019; 9(4). PMC: 6523883. DOI: 10.3390/biom9040141. View

13.

Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M . Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011; 79(8):871-82. DOI: 10.1038/ki.2010.530. View

14.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

15.

Hu G, Xu L, Ma Y, Kohzuki M, Ito O . Chronic exercise provides renal-protective effects with upregulation of fatty acid oxidation in the kidney of high fructose-fed rats. Am J Physiol Renal Physiol. 2020; 318(3):F826-F834. DOI: 10.1152/ajprenal.00444.2019. View

16.

Kang H, Ahn S, Choi P, Ko Y, Han S, Chinga F . Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2014; 21(1):37-46. PMC: 4444078. DOI: 10.1038/nm.3762. View

17.

Liu Y . Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7(12):684-96. PMC: 4520424. DOI: 10.1038/nrneph.2011.149. View

18.

Villena J . New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J. 2014; 282(4):647-72. DOI: 10.1111/febs.13175. View

19.

Lv J, Zhang L . Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019; 1165:3-15. DOI: 10.1007/978-981-13-8871-2_1. View

20.

HaoShang , Jia X, Liu H, Zhang X, Shao Y . A comprehensive review of emodin in fibrosis treatment. Fitoterapia. 2022; 165:105358. DOI: 10.1016/j.fitote.2022.105358. View